Tumor-Specific Clonal Neoantigen (Clonal Neoantigen)

Tumor-specific clonal neoantigens are unique antigenic peptides derived from somatic mutations present in all cancer cells within a tumor. They are presented on MHC molecules and can be recognized by T cell receptors, making them promising targets for cancer immunotherapy due to their tumor-specificity and potential to elicit strong anti-tumor immune responses.

Other names

Clonal neoantigenTumor-specific neoantigenShared neoantigenDriver mutation-derived neoantigen

Varies depending on the immunotherapy: ICIs enhance T cell activity against neoantigen-expressing cells; vaccines prime the immune system to recognize neoantigens; adoptive T-cell therapies use engineered T-cells to target neoantigens; bispecific antibodies redirect T-cells to neoantigen-expressing cells.